The BBB is to protecting the brain internally as the
skull is to protecting it externally. The problem is the BBB does not
differentiate what it keeps out. Life-saving chemicals, if they happen to be
the wrong chemicals, simply won't get through. With very few exceptions, only
small molecules soluble in fat clear the barrier. Only two percent of
small-molecules get through. These include alcohol, caffeine, and nicotine.
Small-molecule compounds have been used to treat
affective disorders, schizophrenia, chronic pain, and epilepsy, but they leave
a lot to be desired. The problem, says William Pardridge MD of UCLA writing in
the Jan 2003 Archives of Neurology, is that "small molecules are largely
palliative medicines with often unfavorable safety profiles."
Dopamine is one of those types of small molecules,
but unfortunately, their chemical structure stops them from passing the BBB.
However, L-DOPA can follow a certain type of amino acid transporter through the
BBB without even knowing it.
Dr. Pardridge and his team have been experimenting
on encasing genes in liposomes coated with what they called a special polymer
in order to attach them with antibodies. Why antibodies? The antibodies are the
ones that sneak their way pass the brain-capillary receptors so the liposomes
could complete their mission. In one of their experiments, they injected rats
that had Parkinson’s with liposomes containing a gene that “boosts production
of the enzyme tyrosine hydroxylase,” (a building block of dopamine). The rats’
abnormal symptoms were then reduced up to 70% three days later. By completing
multiple experiments with the same procedures, rats with brain tumors doubled
their lifespans. With weekly injections, delivery of antisense RNA that blocked
production of a malignant growth factor was a success.
What’s the point in finding the cure to a
neurological disease, if there is a high possibility that it won’t even make it
pass through the BBB in order to receive
the full effect? Since there is no
academic neuroscience program that focuses on BBB transport biology or drug targeting,
who knows how long it would take for it to become funded with the technology
and research. For example, if someone is
trying to sell you a product that is 99% effective, wouldn’t you feel more
confident if it had that one last percent? But once again, the Blood-Brain Barrier only has a two percent chance for the medication to become in full-effect.
So would you take that risk? These are the kind of things that makes you
wonder.